CANF - Can-Fite BioPharma Ltd.

NYSE American - Nasdaq Real Time Price. Currency in USD
3.1900
-0.2900 (-8.33%)
As of 11:03AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.4800
Open3.4500
Bid3.1300 x 1200
Ask3.1700 x 4000
Day's Range3.0900 - 3.4000
52 Week Range2.9100 - 25.9500
Volume279,071
Avg. Volume199,767
Market Cap5.864M
Beta (3Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-5.0700
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Can-Fite BioPharma Announces $6 Million Registered Direct Offering

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive agreement with certain institutional investors to receive gross proceeds of $6 million. In connection with the offering, the Company will issue 1,500,000 registered American Depository Shares (ADSs) of Can-Fite at a purchase price of $4.00 per ADS in a registered direct offering.  Additionally, for each ADS purchased by investors, the investors will receive an unregistered warrant to purchase one ADS.  The warrants will have an exercise price of $4.00 per ADS, will be immediately exercisable and will expire five and one-half years from the issuance date.  The closing of the offering is expected to take place on or about May 22, 2019, subject to the satisfaction of customary closing conditions.

  • Benzinga2 days ago

    Can-Fite Abstract Selected For Liver Conference

    Shares of the biotech  Can-Fite Biopharma Ltd (NASDAQ: CANF ) were skyrocketing Monday after an abstract describing data from the company's liver cancer study of the drug namodenoson was selected by the ...

  • Business Wire2 days ago

    Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)

    PETACH TIKVA, Israel-- -- The International Liver Cancer Association Annual Conference has selected the Can-Fite abstract for presentation Phase III trial for Namodenoson in advanced liver cancer is now under preparation Namodenoson has both Fast Track status and Orphan Drug designation from the U.S. FDA Can-Fite BioPharma Ltd . , a biotechnology company with a pipeline of proprietary small molecule ...

  • Business Wire16 days ago

    Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it is conducting preparatory work for a planned pivotal Phase III study of its drug candidate Namodenoson in the treatment of advanced liver cancer in patients as a first line and second line treatment. Namodenoson was found to increase overall survival in hepatocellular carcinoma (HCC) patients with Child Pugh B7, the largest subpopulation of the study, as compared to placebo, even though the trial did not meet its primary endpoint.

  • Business Wire21 days ago

    Can-Fite Announces ADS Ratio Change

    On the effective date, each ADS holder will be required to exchange every fifteen (15) ADSs then held for one (1) new ADS. The Bank of New York Mellon, the depositary bank, will arrange for the exchange of the current ADSs for the new ones.

  • Business Wirelast month

    Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea

    Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it has received a $1,000,000 payment from Chong Kun Dang Pharmaceuticals (CKD) (Korean Stock Exchange: 185750.KS) of South Korea. CKD has licensed the distribution rights to Namodenoson in South Korea for the treatment of liver cancer and non-alcoholic steatohepatitis (NASH) in a deal totaling $6,000,000 in upfront and milestone payments, plus a transfer price for delivering finished products to CKD.

  • Business Wirelast month

    Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting

    PETACH TIKVA, Israel-- -- Acceptance for late breaking oral presentation underscores the oncology community’s interest in Namodenoson as a potential treatment for liver cancer Can-Fite now preparing for Phase III study of Namodenoson in patients with advanced liver cancer Child Pugh B 7 cirrhosis with Key Opinion Leader as Principal Investigator Can-Fite BioPharma Ltd . , a biotechnology company with ...

  • Business Wire2 months ago

    Can-Fite BioPharma Announces $3.2 Million Registered Direct Offering

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive agreement with certain institutional investors to receive gross proceeds of approximately $3.2 million. In connection with the offering, the Company will issue 4,923,078 registered American Depository Shares (ADSs) of Can-Fite at a purchase price of $0.65 per ADS in a registered direct offering.

  • Business Wire2 months ago

    Can-Fite Files Annual Report for the Year Ended December 31, 2018

    Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S.

  • Business Wire2 months ago

    Can-Fite Reports 2018 Financial Results & Provides Clinical Update

    PETACH TIKVA, Israel-- -- Global distribution deals signed in Europe and China, including Can-Fite’s largest deal to date for up to $74.5 M Top-line data from Phase II Namodenoson trial in the treatment of liver cancer supports continuation into Phase III study Top-line Data from Phase II NASH Study with Namodenoson expected in H2 2019 Patient enrollment continues in two Phase III studies for Piclidenoson ...

  • Business Wire2 months ago

    Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson

    The study did not achieve its primary end point of median overall survival in the whole population of 78 patients, however, superiority in median overall survival was found in the largest study subpopulation of 56 patients and in secondary end points including objective response in the whole population, strongly supporting the progression into Phase III.

  • ACCESSWIRE2 months ago

    Four Marijuana Stocks on the Rise on Wednesday

    Whereas in the past, society largely condemned cannabis and refused to consider the potential benefits of investing in cannabis and/or utilizing cannabis products, those feelings are slowly dissipating. The positive shift in public opinion can be attributed to the fact that the medical community has released data supporting the use of cannabidiol as a form of alternative treatment, given its effectiveness as an anti-inflammatory. Like other sectors whirring with innovation, the cannabis industry is rapidly progressing into the future and, rather than be left behind, investors looking for potential opportunities may want to keep cannabis companies on their radars.

  • Business Wire3 months ago

    Can-Fite to Participate in Bio Asia International Conference on March 5-6, 2019 in Tokyo

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the Company’s VP of Business Development, Sari Fishman will participate in the Bio Asia International Conference in Tokyo, Japan on March 5th and 6th, 2019. The BIO Asia International Conference brings together the global biotechnology and pharmaceutical industry to explore licensing collaborations and investor engagement in the current Asia-Pacific business and policy environments.

  • Business Wire3 months ago

    Can-Fite Expands its Namodenoson Distribution Deal with CKD in South Korea with NASH Indication

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the expansion of its distribution agreement with Chong Kun Dang Pharmaceuticals (CKD) (Korean Stock Exchange: 185750.KS) in South Korea, for the indication of non-alcoholic steatohepatitis (NASH).

  • ACCESSWIRE4 months ago

    Watch These 4 Healthcare Stocks Set The Pace On Monday (2/4/19)

    Over time, in an effort to further these advancements in the healthcare industry, legislators have sought to pass positive legislation in favor of legalizing marijuana, resulting in the passing of the US Farm Bill as well as other laws around the world. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Can-Fite BioPharma Ltd (CANF), BioLineRx Ltd (BLRX), and Aurora Cannabis Inc., (ACB) represent four cannabis companies determined to develop nuanced approaches for integrating cannabis as a means for improving the quality of life for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • Business Wire4 months ago

    Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug

    Osteoarthritis is a common joint disease impacting ageing populations and represents an $8 billion global treatment market in 2017 and is expected to rise to $11.6 billion by the end of 2025 according to Persistence Market Research.

  • ACCESSWIRE4 months ago

    4 Healthcare Stocks Raising The Bar On Wednesday (1/30/19)

    With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Co-Diagnostics Inc (CODX), Can-Fite BioPharma Ltd (CANF), and Eyenovia Inc (EYEN) represent four healthcare companies determined to develop and distribute the best quality healthcare options for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • Business Wire4 months ago

    Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

    Can-Fite’s Piclidenoson, a Phase III drug candidate, and Namodenson, a Phase II drug candidate, both target the A3 adenosine receptor (A3AR), which the Company believes may treat cytokine release syndrome (CRS) while also promoting an anti-cancer effect.

  • Business Wire4 months ago

    Can-Fite BioPharma CEO Letter to Shareholders

    It has been a very busy and productive year at Can Fite BioPharma, filled with clinical and business development activities. During 2018, we continued to enroll patients for the ACRobat™ Phase III trial of our lead drug candidate, Piclidenoson, in the treatment of rheumatoid arthritis and in August 2018, we initiated patient enrolment for a the Comfort™ Phase III psoriasis trial.

  • Business Wire4 months ago

    Can-Fite BioPharma Announces Registered Direct Offering

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it has entered into a definitive agreement with a single institutional investor to receive gross proceeds of approximately $2.35 million. In connection with the offering, the Company will issue 2,238,096 registered American Depository Shares (ADSs) of Can-Fite at a purchase price of $1.05 per ADS in a registered direct offering.

  • Business Wire4 months ago

    Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent

    Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced new pre-clinical findings demonstrating that Namodenoson, inhibits lipid production and fat accumulation in adipocytes (lipid producing cells). These findings together with the excellent safety profile of Namodenoson support its potential utilization as an anti-obesity drug. New pre-clinical studies of Namodenoson showed a significant decrease in lipid production and fat accumulation utilizing 3T3-L1 adipocytes, functioning as lipid producing cells and are also responsible for fat storage.

  • Business Wire5 months ago

    Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference

    Can-Fite’s near term milestones include data release from a Phase II study with its Namodenoson drug in patients with advanced liver cancer which is expected in Q1/19. In addition, the Company is actively enrolling NAFLD/NASH patients for a Phase II study of Namodenoson.

  • Business Wire5 months ago

    Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson’s Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC

    The agreement will support research directed by Scott Friedman, M.D., Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine. The research is aimed at transcriptomic and molecular analyses to further explore the mechanisms of action of Namodenoson (CF102) in human hepatic stellate cells in order to clarify its effect on fibrogenesis that occurs in non-alcoholic steatohepatitis (NASH).

  • Business Wire6 months ago

    Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update

    Revenues for the Nine Months Ended September 30, 2018 Were $3.5 Million Compared to $0.7 Million for the Same Period in 2017

  • Business Wire6 months ago

    Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert

    PETACH TIKVA, Israel-- -- Dr. Josep Llovet is a Key Opinion Leader in the field of liver diseases Data from Phase II study in advanced liver cancer are expected during Q1 2019 Can-Fite BioPharma Ltd . , a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced that Professor Josep Llovet, an experienced leader with deep ...